<DOC>
	<DOCNO>NCT00687219</DOCNO>
	<brief_summary>The objective evaluate efficacy safety combination therapy peginterferon alfa-2b 1.0 Âµg/kg/week subcutaneous ( SC ) + ribavirin administer 48 week participant chronic hepatitis C type C compensate liver cirrhosis . Participants hepatitis C virus ribonucleic acid ( HCV-RNA ) positive 24 week treatment discontinue therapy .</brief_summary>
	<brief_title>Efficacy Safety Peginterferon Alfa-2b Ribavirin Therapy Subjects With Type C Compensated Liver Cirrhosis ( Study P05116 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adults age 2070 year . Positive quantitative serum HCVRNA . Participants classify A ChildPugh classification , ascites hepatic encephalopathy . Diagnosed type C compensate liver cirrhosis base liver biopsy perform within 3 year late celioscopy . Prolonged prothrombin time &lt; =3.0 sec . Participants partner participant willing use adequate contraception course study . Participants hospitalize least 14 day since treatment initiation . Weight &gt; 40 kg &lt; =100 kg Hematology laboratory result : hemoglobin &gt; =12 g/dL neutrophil count &gt; =1,500/mm^3 platelet count &gt; =70,000/ mm^3 Blood chemistry result : albumin direct bilirubin within normal limit alpha fetoprotein ( AFP ) within reference range AFPL3 &lt; =10 % Protein induce vitamin K ( PIVKA ) II &lt; =100 mAU/mL Participants previously respond virologically combination therapy interferon ( include polyethylene glycolmodified interferon ) ribavirin Participants previously receive treatment interferon least 90 day elapse since end previous treatment Participants receive treatment within 14 day prior registration injectable preparation contain glycyrrhizin/cysteine/glycyron shosaikoto Participants receive administration drug antiviral , antitumor , immunomodulating effect ( include glucocorticoid radiation therapy ) within 90 day prior registration ( exclude local administration topicals ) Participants receive investigational drug within 180 day prior registration Hepatitis B surface ( HBs ) antigen positive Antinuclear antibody &gt; =320 time Serum creatinine exceed upper limit reference range Participants fast blood glucose &gt; =110 mg/dL ( participant fast blood glucose &gt; =110 mg/dL &lt; 126 mg/dL register hemoglobin A1C ( HbA1c ) &lt; 6.5 % ) [ fast blood glucose measure participant receive treatment diabetes mellitus ] Participants follow : diabetes mellitus require treatment ; thyroid function disorder control treatment ; liver disease autoimmune , alcoholic druginduced liver disease ; hemophilia ; arrhythmia require treatment ; coexist hypertension control drug therapy ( systolic blood pressure [ BP ] &gt; =160mmHg diastolic BP &gt; =100mmHg ) ; chronic pulmonary disease ; hemoglobinopathy ( thalassemia , sickle cell anemia ) ; malignant tumor history malignant tumor within past 5 year ; organ transplant ( cornea hair transplant ) Participants history primary biliary cirrhosis , liver failure , hepatic carcinoma ; decompensated liver cirrhosis follow disease : ascites , jaundice , variceal hemorrhage , esophageal gastric varix require treatment , hepatic encephalopathy , idiopathic bacterial peritonitis ; depression schizophrenia require treatment , suicidal attempt suicidal ideation ; epileptic seizure require treatment ; angina , cardiac failure , myocardial infarction , lifethreatening arrhythmia ; autoimmune disease ( Hashimoto 's disease , Crohn 's disease , ulcerative colitis , chronic rheumatoid arthritis , idiopathic thrombocytopenic purpura , systemic erythematosus , autoimmune hemolytic anemia , scleroderma , etc . ) ; hepatic carcinoma Participants history hypersensitivity interferon preparation , biological product vaccine , nucleoside analog , specific reaction pegylated interferon alfa2b prick test conduct initiation treatment Women pregnant nursing well woman pregnancy rule serum human chorionic gonadotropin ( HCG ) test conduct screening period . Male participant partner pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hepatitis C</keyword>
</DOC>